Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
about
Androgen deprivation therapy as backbone therapy in the management of prostate cancerPharmacologic blockade and genetic deletion of androgen receptor attenuates aortic aneurysm formation.Maximal androgen blockade for advanced prostate cancer.Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects.Future prospects in prostate cancer.Hormonal and Chemotherapeutic Systemic Therapy for Metastatic Prostate Cancer.Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support.New developments in the use of monoclonal antibodies in the therapy of genitourinary cancer.The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer ModelHormonal treatment for prostate cancer.Nilutamide: an antiandrogen for the treatment of prostate cancer.Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.Controversies surrounding androgen deprivation for prostate cancer.Hormonal therapy in metastatic prostate cancer: current perspectives and controversiesEndocrine and adrenergic pharmacological intervention in diseases of the prostateMaximal androgen blockade for the treatment of metastatic prostate cancer--a systematic reviewCombination hormonal therapy: a reassessment within advanced prostate cancer.Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility.Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.Concept and viability of androgen annihilation for advanced prostate cancer.Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial.The palliative therapy of advanced prostate cancer, with particular reference to the results of recent European clinical trials.Combined androgen blockade in the treatment of advanced prostate cancer--an overview. The Scandinavian Prostatic Cancer Group.Controversies in the management of advanced prostate cancer.Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.Climacteric-like disorders in prostate cancer patients treated with LHRH agonists.Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.
P2860
Q28071795-83EFBCC9-AEF5-479B-9EB9-9C4B6D3501CAQ30277664-59DBEE20-A442-4610-B7D0-3ED94B801D6CQ30868300-AE6EACF2-E20D-4BEF-800A-9DA7E811725DQ33610869-814608D8-1636-4BFC-B993-C70FBC17F95FQ33695955-965F9A41-0C1A-46DD-AC35-E27A3D85EFA8Q33891545-C08EFE5E-C059-482C-A5FB-6D0BC7759FE8Q33910607-177BDD88-2BE6-4227-929D-65F983051858Q33962000-B329BDAE-2697-4A74-8523-890FAEF49747Q34037498-8803E75E-4297-4AC8-83B8-089AB80FF6F2Q34167174-8C0FF519-3CE5-4A34-BC97-26F894603F0BQ34413500-0681CFCB-8E73-4C01-979D-1D7786C69528Q34452166-785317CA-FDA0-4646-A336-6B1469455546Q34747437-9872EA52-DD9F-4C91-B602-ACB35D18E138Q34849222-80EA4DD3-9BAB-4D5B-9A7B-C300BC091676Q35569303-DD52BC61-CC98-434D-A7FB-6FAEDEE9C641Q35803015-9BD88617-5AEC-4AF7-BAF7-F641D0714FC1Q35840364-B1D9B01A-2AD5-4B24-BAC0-188F40E4D618Q35886568-B8496EE6-915F-4A23-A1A2-2151095E4D15Q36039229-31035D39-67A8-4623-BA6F-FDBC9E1E8FC8Q36381291-7A9A5368-60DA-43B2-BF5E-9D77FB410649Q38207556-7E6419D5-27F2-4FCE-A7A6-2D10FDABDC93Q38803536-15D7B313-F341-44B1-9910-8EAF1726AE6FQ39486360-3B04B64C-47CA-49C1-BFCF-7F30DA31F9A4Q41409558-C2A814C5-5A4F-4F98-8EF2-9A88DE2DE0EBQ41556362-C63F7CA2-C417-4FC5-8700-BCCCA80AAD95Q42135671-4215C435-1F87-4AC5-BAC3-DC5E8233EA61Q43629563-FF61CFC9-35AD-42D7-B518-DED93D102314Q43937942-4E0D66F6-DF80-40ED-B8A1-F045BDA68940Q48559346-30A0CEAD-089B-4775-BC35-66692CC1FA00Q53558519-6BE8B7D1-6B9E-442F-A299-D73BAF84BE59Q55194983-47B526DC-3619-4E18-B1D3-D384FFCF1F44
P2860
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Goserelin acetate and flutamid ...... U Group and EORTC Data Center.
@ast
Goserelin acetate and flutamid ...... U Group and EORTC Data Center.
@en
type
label
Goserelin acetate and flutamid ...... U Group and EORTC Data Center.
@ast
Goserelin acetate and flutamid ...... U Group and EORTC Data Center.
@en
prefLabel
Goserelin acetate and flutamid ...... U Group and EORTC Data Center.
@ast
Goserelin acetate and flutamid ...... U Group and EORTC Data Center.
@en
P2093
P1433
P1476
Goserelin acetate and flutamid ...... U Group and EORTC Data Center.
@en
P2093
Carnelro de Moura JL
Sylvester R
P304
119-29; discussion 129-30
P356
10.1016/0090-4295(93)90634-M
P407
P577
1993-08-01T00:00:00Z